Suzhou Ribo wins EMA approval for Phase 2b vortosiran trial in stroke prevention for atrial fibrillation

PUBT · 2d ago
Suzhou Ribo wins EMA approval for Phase 2b vortosiran trial in stroke prevention for atrial fibrillation
  • Suzhou Ribo Life Science secured European Medicines Agency clearance to start a Phase 2b trial of vortosiran for stroke prevention in atrial fibrillation.
  • The ORBIT-XI-AF study advances the company’s Factor XI-targeting siRNA program into multi-regional clinical development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260728-12259332), on July 28, 2026, and is solely responsible for the information contained therein.